Last reviewed · How we verify
Ticagrelor 60
Ticagrelor 60 mg is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events.
Ticagrelor 60 mg is a P2Y12 platelet receptor antagonist that inhibits platelet aggregation and reduces thrombotic events. Used for Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events, Secondary prevention of atherothrombotic events in patients with prior myocardial infarction.
At a glance
| Generic name | Ticagrelor 60 |
|---|---|
| Sponsor | Sheffield Teaching Hospitals NHS Foundation Trust |
| Drug class | P2Y12 receptor antagonist (antiplatelet agent) |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Ticagrelor binds to the P2Y12 adenosine diphosphate (ADP) receptor on platelets, preventing platelet activation and aggregation. This antiplatelet effect reduces the risk of stent thrombosis and cardiovascular events in patients with acute coronary syndrome or those requiring percutaneous coronary intervention. The 60 mg dose is a lower maintenance dose used for long-term secondary prevention in certain patient populations.
Approved indications
- Acute coronary syndrome (ACS) for prevention of thrombotic cardiovascular events
- Secondary prevention of atherothrombotic events in patients with prior myocardial infarction
Common side effects
- Bleeding
- Bradycardia
- Dyspnea
- Ventricular pauses
Key clinical trials
- Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention (PHASE4)
- STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT (NA)
- Ultrathin-strut Biodegradable Polymer Sirolimus-eluting Stents With P2Y12 Inhibitor-based Single Antiplatelet Therapy vs. Conventional DAPT for Unprotected Left Main Coronary Artery Disease (ULTIMATE-LM) (NA)
- Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea (NA)
- Ticagrelor De-escalation Strategy in AMI Patients (PHASE4)
- Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI (PHASE4)
- Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease (PHASE4)
- A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor 60 CI brief — competitive landscape report
- Ticagrelor 60 updates RSS · CI watch RSS
- Sheffield Teaching Hospitals NHS Foundation Trust portfolio CI